Competitive and Market Trend Analysis of Gastroesophageal Reflux Disease Therapeutics Industry Through 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Latest Market Insights for the Gastroesophageal Reflux Disease Therapeutics Industry?
The market size for therapeutics in gastroesophageal reflux disease has seen a stable growth in the past years. Its growth is expected to rise from $5.93 billion in 2024 to $6.08 billion in 2025, exhibiting a Compound Annual Growth Rate (CAGR) of 2.5%. The increase during the historical period can be associated with evolving lifestyles and dietary patterns, an aging demographic, growth in awareness and diagnoses, the prevalence of stressful lifestyles, and an augmentation in obesity rates.
The market for therapeutics addressing gastroesophageal reflux disease is projected to witness significant expansion in the upcoming years, with its value anticipated to reach $7.74 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.2%. The predicted growth during this forecast period is largely due to the surge in demand for innovative treatments, the increasing elderly population, bespoke medicine strategies, emphasis on non-drug interventions, and the advent of biological and pioneering therapies. The forecast period is expected to see prevalent trends like alternative treatments and mind-body methodologies, increased studies on gut wellbeing, the rise of care models centred around patients, targeted awareness campaigns for GERD, and the incorporation of digital health tools.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12058&type=smp
What Forces Are Driving The Growth Of The Gastroesophageal Reflux Disease Therapeutics Industry?
The gastroesophageal reflux disease therapeutics market is predicted to grow due to the increasing incidence of gastroesophageal reflux disease. This chronic ailment, characterized by the flow of stomach acid backward into the esophagus, leads to symptoms such as heartburn, regurgitation, and potential complications. GERD therapeutics are designed to manage and mitigate acid reflux symptoms by balancing gut pH, regulating inflammation, and supporting esophageal function. According to a September 2022 WebMed article, an online US health news and information publisher, over 60 million American adults experience heartburn at least once a month, and over 15 million have daily symptoms. Moreover, the National Library of Medicine, a US federal medical library, revealed in July 2022 that GERD is one of the most frequently diagnosed digestive diseases in the United States. It has a prevalence of 20%, resulting in high direct and indirect healthcare costs and negatively impacting life quality. Thus, the high incidence of gastroesophageal reflux disease is likely to fuel the gastroesophageal reflux disease therapeutics market’s growth.
What Is The Overview Of Market Segmentation In The Gastroesophageal Reflux Disease Therapeutics Industry?
The gastroesophageal reflux disease therapeutics market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class
3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Supermarkets
4) By Application: Crohn’s Disease, Gastroesophageal Reflux Disease (GERD), Ulcerative Colitis
Subsegments:
1) By Branded: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antacids, Coating Agents
2) By Generic: Generic Proton Pump Inhibitors (PPIs), Generic H2-Receptor Antagonists, Generic Antacids, Generic Coating Agents
What Future Market Trends Are Projected For The Gastroesophageal Reflux Disease Therapeutics Industry?
In the therapeutics market for gastroesophageal reflux disease, it is evident that product innovation is becoming increasingly important. To maintain their competitive edge in the market, leading companies are putting emphasis on the development of novel treatments. For example, Phathom Pharmaceuticals, a biopharmaceutical company located in the US, made a significant move in November 2023. They introduced VOQUEZNA (vonoprazan), a potassium-competitive acid blocker authorized for curing and maintaining all levels of erosive esophagitis, as well as mitigating heartburn linked with both erosive and non-erosive GERD. The clinical trials produced impressive results, demonstrating a 93% healing rate among patients administered the 20 mg dose, a noticeable improvement from the 85% healing rate for the prevalent proton pump inhibitor (PPI) lansoprazole.
Who Are The Primary Players Operating Across The Global Gastroesophageal Reflux Disease Therapeutics Market?
Major companies operating in the gastroesophageal reflux disease therapeutics market include Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic PLC, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, bioMerieux SA, Teva Pharmaceutical Industries, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., EndoGastric Solutions, RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited
Get The Full Report Here:
Which Region Offers The Most Growth Potential For The Gastroesophageal Reflux Disease Therapeutics Market Through 2029?
North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12058&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
